Identification of poxvirus CD8⁺ T cell determinants to enable rational design and characterization of smallpox vaccines

David C. Tscharke,¹,² Gunasegaran Karupiah,³ Jie Zhou,³ Tara Palmore,¹ Kari R. Irvine,¹ S.M. Mansour Haeryfar,¹ Shanicka Williams,¹ John Sidney,⁴ Alessandro Sette,⁴ Jack R. Bennink,¹ and Jonathan W. Yewdell¹

¹Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892
²EBV Biology Laboratory, Division of Immunology and Infectious Diseases, Queensland Institute of Medical Research, Herston, QLD 4006, Australia
³Division of Immunology and Genetics, John Curtin School of Medical Research, Australian National University, Canberra, ACT 2601, Australia
⁴Division of Translational Immunology and Biodefense, La Jolla Institute for Allergy and Immunology, San Diego, CA 92121

The large size of poxvirus genomes has stymied attempts to identify determinants recognized by CD8⁺ T cells and greatly impeded development of mouse smallpox vaccination models. Here, we use a vaccinia virus (VACV) expression library containing each of the predicted 258 open reading frames to identify five peptide determinants that account for approximately half of the VACV-specific CD8⁺ T cell response in C57BL/6 mice. We show that the primary immunodominance hierarchy is greatly affected by the route of VACV infection and the poxvirus strain used. Modified vaccinia virus ankara (MVA), a candidate replacement smallpox vaccine, failed to induce responses to two of the defined determinants. This could not be predicted by genomic comparison of viruses and is not due strictly to limited MVA replication in mice. Several determinants are immunogenic in cowpox and ectromelia (mousepox) virus infections, and immunization with the immunodominant determinant provided significant protection against lethal mousepox. These findings have important implications for understanding poxvirus immunity in animal models and benchmarking immune responses to poxvirus vaccines in humans.

In the late 1700s, Edward Jenner published the seminal observation that infection with animal poxviruses protects humans against smallpox (1). Though similar practices had been followed for centuries by other societies around the world, Jenner was the first to apply the scientific method to evaluating efficacy. In so doing, he laid the foundations for both the eradication of smallpox and for the discipline of immunology.

Despite its historic origins, current understanding of the molecular basis for cross-protection between heterologous poxviruses is woefully incomplete. This is particularly the case for antigens recognized by T cells, although they are assumed to play an important role in immunity (2–4). The neglect stems partly from the daunting size of poxvirus genomes and from the lack of a pressing need to understand poxvirus immunology after the eradication of smallpox (2). Recent improvements in molecular methods and determinant prediction have made genome size less of an obstacle. The specter of variola virus (VARV), the causative agent of smallpox, being used as a bioweapon has eliminated complacency about human poxvirus immunity (5). The current live vaccinia virus (VACV)-based smallpox vaccine, while remarkably effective, is associated with mild to severe complications and safer alternatives are required.

As a consequence, identification of human T cell determinants of VACV, the current smallpox vaccine, is now underway. To date, papers have been limited to a few determinants presented by a single restricting class I molecule (6–8). Although this work is important for characterizing human responses to safer vaccines, the biological relevance of responses to these determinants cannot be tested. Fortu-
Mice were infected with 10<sup>6</sup> PFU VACV i.p. and 7 d later, purified CD8<sup>+</sup> genes (top left) as part of a 96-well array were used as stimulators. IFN-γ-restricted CD8<sup>+</sup> from the original screening assays used to identify VACV genes with Kb-cells (a) or splenocytes (b) were used in ICS assays. (a) Examples taken this same virus protects mice against mousepox (9, 10).

For example, just as VACV protects humans against smallpox, there are animal models to shed light on the problem of cross-protection between heterologous poxviruses. For example, just as VACV protects humans against smallpox, this same virus protects mice against mousepox (9, 10).

Mousepox is caused by ectromelia virus (ECTV), a mouse pathogen closely related to VACV and VARV (11, 12). Current understanding of smallpox pathogenicity owes much to pioneering work with mousepox (13, 14) and more recent work has taught us much about immunity in systemic poxvirus disease (15–17). Alternative models for lethal poxvirus disease in mice have also been exploited, including intranasal VACV (6, 8, 18–20) and cowpox virus (CPXV; reference 21) infection. Although the specificities of T cells that contribute to protection of humans against smallpox and mice against various poxviruses will not be identical due to differences in antigen processing and presentation and T cell receptor repertoires, the basic principles underlying protection are likely to be similar. Due to the sophistication of the mouse model for immunity, many important questions about the basic immunology of poxvirus protection are best addressed at this time in mouse models. These include assessment of the importance of individual effector mechanisms and the degree and mechanism of protection afforded by smallpox vaccine candidates.

A critical step in refining the mouse model is to define poxvirus determinants recognized by CD8<sup>+</sup> T cells and determine their role in protective immunity. Here, we provide the original description of poxvirus determinants recognized by mouse CD8<sup>+</sup> T cells, and their biological relevance in protection against lethal poxvirus infections.

**RESULTS**

Identification of VACV CD8<sup>+</sup> T cell determinants in mice

To identify immunogenic VACV gene products, we generated an expression library of 258 predicted open reading frames (ORFs) and highly transfecatable cells (human 293 cells) expressing H-2K<sup>b</sup> or D<sup>b</sup>. Cells transfected with individual plasmids were tested for their ability to induce IFN-γ expression in CD8<sup>+</sup> T cells derived from C57BL/6 mice infected i.p. with VACV 7 d previously (Fig. 1 a). Five antigenic VACV ORFs were discovered, three restricted by H-2K<sup>b</sup> and two by H-2D<sup>b</sup> (Table I). For two ORFs, A19L and A47L, this is the first empirical evidence that they are expressed during infection. Ironically, of the known genes, two (B8R and K3L) are involved in virus evasion of host interferon responses (22). Whether this apparent targeting of immune modulators by CD8<sup>+</sup> T cells is a general phenomenon or a quirk of the mouse model used requires more determinants to be mapped in mice and other species.

Antigenic VACV ORFs were analyzed in silico for peptides matching the relevant class I peptide-binding motif. Synthetic peptides for predicted determinants were tested for their ability to bind the relevant class I allomaporph and to activate CD8<sup>+</sup> T cells from VACV-infected mice (Table I). None of the predicted A42R peptides were immunogenic, which led to testing subclones expressing gene fragments (residues 1–48, 1–82, 75–end, and 107–end) and ultimately a second round of in silico prediction resulting in identification of YAPVSPV1 as the determinant.

Synthetic peptides for each of the five mapped determinants were antigenic at <10<sup>−10</sup> M (Fig. 1 b) when tested for their ability to activate primary VACV-specific CD8<sup>+</sup> T cells. Peptide-specific CD8<sup>+</sup> T cell cultures were generated by in vitro stimulation of splenocytes from VACV-infected mice over several weeks. Cultures stimulated with the five peptides were found to recognize VACV-infected DC2.4 cells and VACV-infected 293 expressing the correct restric-
tion element (unpublished data). Similar cultures recognized 293 cells expressing the appropriate restriction element transfected with the source VACV gene, but not another gene, or the source gene where the wrong restriction element was present (unpublished data). This strongly suggests that the peptides identified represent bona fide virus-encoded determinants generated by antigen processing pathways and not spuriously cross-reacting peptides. We note that the odds of this latter possibility increase with increasing genome size of the immunogen and might prove to be particularly relevant to poxviruses and other large DNA viruses.

Contribution of mapped determinants to total response

We determined the contribution of these determinants to the total acute (day 7; Fig. 2a) and memory (day 21; Fig. 2b) CD8+ T cell response to VACV by intracellular cytokine staining (ICS) of splenocytes tested ex vivo. Uninfected mice failed to detectably respond to any of the peptides (unpublished data). 7 d after i.p. infection, B8R20-27 elicited a response from 10–15% of all splenic CD8+ T cells, amounting to a staggering $10^7$ cells in the spleen alone. Other determinants elicited a more modest response; in general, K3L6-15 was the next strongest followed by A47L138-146, A42R88-96, and A19L47-55. Occasionally, in individual mice, the order of K3L6-15 and A47L138-146 was swapped in the immunodominance (ID) hierarchy, but A19L47-55 was always at the bottom. The stability of the VACV ID hierarchy in individual mice is similar to that seen with influenza virus (23). Comparing determinant-specific responses with the total VACV-specific response shows that B8R20-27, the immunodominant determinant (IDD), alone stimulates about 25% of the total response. When combined with the four subdominant determinants (SDDs), this accounts for up to 40% of the total response.

As expected, CD8+ T cell numbers decreased in memory CD8+ T cells, which were also measured ex vivo by ICS. The ID hierarchy was slightly altered, due to a less pronounced decrease in A47L138-146-specific CD8+ T cells. Similar relative sparing of CD8+ T cells specific for SDDs in memory has been observed previously (24). Altogether, the CD8+ T cells specific for the defined determinants account for >30% of the total anti-VACV memory CD8+ T cell response.

Table I. Immunogenic proteins, peptides tested, and CD8+ T cell epitopes

<table>
<thead>
<tr>
<th>Gene</th>
<th>H-2</th>
<th>Function</th>
<th>Time</th>
<th>Peptides tested</th>
<th>IC50 (nM)</th>
<th>Determinant</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>B8R</td>
<td>K</td>
<td>soluble IFN-γ receptor</td>
<td>early</td>
<td>TSYKFESV</td>
<td>0.19</td>
<td>TSYKFESV</td>
<td>B8R20-27</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>WQTMYTNY</td>
<td>6.6</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>ISLKNYGI</td>
<td>16</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>LAVLFINSI</td>
<td>28</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>KVEEYCTGL</td>
<td>129</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>VSLDYINTM</td>
<td>0.77</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>SDITKVS</td>
<td>1,261</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>VKISDITK</td>
<td>4,930</td>
<td></td>
<td></td>
</tr>
<tr>
<td>A19L</td>
<td>K</td>
<td>unknown</td>
<td>–</td>
<td>TIOQRFSSL</td>
<td>1.1</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>AAEFINSL</td>
<td>1.3</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>ATIQRRSSL</td>
<td>1.3</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>VSLDYINTM</td>
<td>7.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>LTPIFSDL</td>
<td>7.3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>A42R</td>
<td>D</td>
<td>profilin homologue</td>
<td>late</td>
<td>YAPVSPIVI</td>
<td>0.24</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>FAKINPGEI</td>
<td>54</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>LMDENTYAM</td>
<td>767</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>MYAPVSPIVI</td>
<td>1,266</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>FAKINPGEI</td>
<td>2,071</td>
<td></td>
<td></td>
</tr>
<tr>
<td>K3L</td>
<td>D</td>
<td>IFN resistance</td>
<td>early</td>
<td>YSLPNAGDVI</td>
<td>0.22</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>YSLPNAGDV</td>
<td>102</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>YIDVNYKRM</td>
<td>5,138</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*a*Class of VACV gene as published: early, late, or unknown.

*b*Top five peptides (by H-2 binding) predicted for each gene. Total peptides tested: B8R, 28; A19L, 3; A47L, 45; A42R, 7; and K3L, 3.

*c*Peptide binding to relevant H-2 molecule.

*d*CD8+ T cell determinant as determined by T cell assays.

*e*Name used for determinant is gene name followed by amino acid position.

As expected, CD8+ T cell numbers decreased in memory CD8+ T cells, which were also measured ex vivo by ICS. The ID hierarchy was slightly altered, due to a less pronounced decrease in A47L138-146-specific CD8+ T cells. Similar relative sparing of CD8+ T cells specific for SDDs in memory has been observed previously (24). Altogether, the CD8+ T cells specific for the defined determinants account for >30% of the total anti-VACV memory CD8+ T cell response.

Route of infection affects ID

Smallpox vaccination has been performed for centuries by dermal scarification, whose simplicity probably contributed to smallpox eradication. To our surprise, after scarification with VACV, B8R20-27-specific responses were enhanced, whereas responses to SDDs were depressed (Fig. 3a). Indeed, in most mice, responses to the two weakest SDDs were reduced to the limit of detection. The enhanced re-
response to B8R_{20-27} is strikingly demonstrated by comparison to the total VACV-specific response; after dermal scarification, >50% of CD8^+ T cells are specific for B8R_{20-27}. To test this apparent suppression of SDD responses more rigorously, the ratio of the sum of the SDD-specific responses to the IDD-specific response was calculated using data from individual mice from several experiments to provide a larger sample size (Fig. 3 b). The mean of this ratio was significantly different (P < 0.0013) between mice infected by the i.p. and dermal routes. Finally, responses to all determinants contribute nearly 60% of the total primary CD8^+ T cell response induced by scarification.

Dryvax immunized mice respond to all mapped determinants

Until this point, we had exclusively used the WR strain of VACV, which was derived from the New York City Board of Health (NYCBH) vaccine strain by serial passage in mice and tissue culture (25). Dryvax (Wyeth Laboratories), the smallpox vaccine currently available in the USA, is the NY-CBH strain propagated on the skin of calves. All determinants were immunogenic in mice infected i.p. with Dryvax. The ID hierarchy was similar to that found with WR; the only determinant with responses that differed significantly was K3L_{6-15} (P < 0.0158; Fig. 4 a). A screen of the VACV ORF library

### Table II. Conservation of immunogenic proteins and determinants across poxvirus species and strains

<table>
<thead>
<tr>
<th>Gene</th>
<th>Determinant</th>
<th>Gene</th>
<th>Determinant</th>
<th>Gene</th>
<th>Determinant</th>
<th>Gene</th>
<th>Determinant</th>
<th>Gene</th>
<th>Determinant</th>
</tr>
</thead>
<tbody>
<tr>
<td>B8R</td>
<td>TSYKFESV</td>
<td>NA/176</td>
<td>Y</td>
<td>202</td>
<td>Y</td>
<td>158</td>
<td>Y</td>
<td>B8R</td>
<td>Y</td>
</tr>
<tr>
<td>A19L</td>
<td>VSLDYINTM</td>
<td>130</td>
<td>Y</td>
<td>152</td>
<td>Y</td>
<td>122</td>
<td>Y</td>
<td>A20L</td>
<td>Y</td>
</tr>
<tr>
<td>A47L</td>
<td>AAFEFINSL</td>
<td>160</td>
<td>Y</td>
<td>185</td>
<td>Y</td>
<td>146</td>
<td>A^e</td>
<td>J1L</td>
<td>Y</td>
</tr>
<tr>
<td>A42R</td>
<td>YAPVSPIVI</td>
<td>154R</td>
<td>Y</td>
<td>179</td>
<td>Y</td>
<td>141</td>
<td>Y</td>
<td>A45R</td>
<td>Y</td>
</tr>
<tr>
<td>K3L</td>
<td>YSLPNAGDVI</td>
<td>024</td>
<td>Y</td>
<td>043</td>
<td>Y</td>
<td>NA</td>
<td>Y</td>
<td>C3L</td>
<td>A^f</td>
</tr>
</tbody>
</table>

^aVACV-MVA: two available sequences (U94848 and AY603355) agree except for B8R, CPX-BR: CPXV-Brighton red, ECTV-Mos: ECTV-Moscow, VARV-Bsh: VARV-Bangladesh.

^bVARV does not infect mice; determinant conservation is shown only for completeness.

^cGene name given where annotated; NA: gene not included in annotation.

^dY: Determinant conserved in genomic sequence; gene may or may not be intact or expressed.

^eA: Determinant is altered to AAFEFINSL.

^fA: Determinant is altered to YSLPNAGDVL.
performed with splenocytes from Dryvax-immunized mice failed to identify novel determinants (unpublished data).

Conservation of immunogenic proteins and determinants across poxvirus strains and species

We searched databases for the presence of immunogenic ORFs in VACV strain modified vaccinia virus ankara (MVA); ECTV strains Naval and Moscow; CPXV strains Brighton red and GRI-90; and VARV strains Bangladesh, India, and VARV minor. Results for different strains from the same species (with the exception of VACV) were identical, so only data from a representative strain of each are included in Table II. All poxviruses have a range of broken, truncated, or otherwise incomplete ORFs, whose annotations are inconsistent. Therefore, where immunogenic ORFs were not annotated (e.g. B8R in the original MVA sequence), we looked for conservation of the sequence encoding the determinants in the genome. In the case of B8R in MVA, the determinant is encoded upstream of the inactivating truncation of the ORF and a more recent sequence has included this ORF in the annotation. Because the promoter sequences are conserved, the determinant should be expressed. On the other hand, K3L function is not conserved in ECTV and while the determinant encoding sequence is present, there are sequence changes in the promoter region that could interfere with expression.

**ID hierarchy is altered in MVA-immunized mice**

MVA is a highly attenuated strain of VACV being developed as a smallpox vaccine replacement (26) and is a potential vector for recombinant vaccines (27). To determine if conservation of genes/determinants in published poxvirus genomes equates with conservation of CD8+ T cells’ immunogenicity and dominance hierarchy, we measured CD8+ T cell responses to i.p. infection with MVA (Fig. 4 b). Though B8R maintained its IDD status, responses to the SDDs were greatly altered relative to WR. Responses to all SDDs were significantly different in MVA compared with WR-infected mice (P < 0.0005 for A47L 138-146, A42R 88-96, and K3L 6-15 and P = 0.014 for A19L 47-55). A19L 47-55, usually the weakest determinant, was the second strongest after MVA immunization at ∼2% of all CD8+ T cells, whereas responses to K3L 6-15 were lower and those to A47L 138-146 and A42R 88-96 were at background levels. The lack of response to the latter two determinants cannot be attributed to genetic variation in the determinants in the MVA strain we used as determined by DNA sequencing. The total VACV-specific response was slightly lower after MVA infection than WR infection, but higher than in Dryvax-immunized mice (unpublished data). We also screened the VACV ORF library with splenocytes from MVA-infected mice, but no new CD8+ T cell determinant–bearing gene products were identified (unpublished data).

These data demonstrate that first, the presence of conserved determinants in conserved ORFs predicted to be expressed provides no guarantee of immunogenicity and, second, the ID hierarchy can be affected by genomic differences in poxviruses not predicted to effect the expression of determinants.

**Responses to mapped determinants are found in mice immunized with attenuated VACVs**

The striking difference in ID hierarchies between WR and MVA could stem from the attenuation of MVA, which, in contrast with WR/Dryvax, is capable of only marginal replication in mammalian cells in vitro and in vivo (27, 28). To examine the relationship between virus attenuation and ID hierarchy, we infected mice with a VACV that only expresses the essential viral structural gene A17L in the presence of IPTG (iA17L; reference 29) and, therefore, cannot...
replicate in vivo. This virus, like many recombinant VACVs, also lacks thymidine kinase and so a thymidine kinase-deficient VACV (VACV-TK\(^\text{−/H11001}\)) is shown as a control for this experiment. VACV-TK\(^{−/H11001}\) replication competent but less pathogenic than WR in vivo (31), and several thymidine kinase-deficient VACVs have been found to have similar ID hierarchies to WR (unpublished data). Despite being unable to replicate in vivo, iA17L generated an ID hierarchy highly similar to TK\(^{−/H11002}\) (Fig. 4 c) or WR (Figs. 2 a and 4, a and b). We conclude that attenuation per se does not lead to significant alterations in ID hierarchy to poxviruses and cannot account for the alterations between CD8\(^{+}\) T cell responses to VACV and MVA.

Identification of VACV-CD8\(^{+}\) T cell determinants by ECTV and CPXV

The protection afforded by the smallpox vaccine relies on cross-reactivity between VACV and VARV. To examine cross-reactivity of poxvirus-specific CD8\(^{+}\) T cell determinants in a mouse system, we extended our characterization of CD8\(^{+}\) T cell responses to include ECTV and CPXV (Fig. 5). B8R\(_{20-27}\) maintained IDD status in responses to both viruses but generated weaker responses when compared with VACV, raising the possibility of other dominant determinants in these viruses. ECTV failed to induce reliable responses to A42R\(_{88-96}\) or K3L\(_{1-15}\). The latter was expected from genomic analysis (Table II). The anti-ECTV response to A47L\(_{138-146}\) was of interest due to a predicted sequence change in the determinant in the second residue (A to T). Using a synthetic version of the altered peptide we confirmed its cross-reactivity with ECTV and VACV-specific CD8\(^{+}\) T cells (unpublished data).

For CPXV infection, B8R\(_{20-27}\), A47L\(_{138-146}\), and K3L\(_{1-15}\) consistently generated responses in individuals, whereas A19L\(_{17-55}\) responses were at the limits of detection. The difficulty to demonstrate A42R\(_{88-96}\) immunogenicity in these experiments may be a reflection of the subcutaneous route of infection, as responses to this determinant were also equivocal after VACV infection by dermal scarification.

Vaccination with the immunodominant VACV determinant leads to partial protection against mousepox

Finally, we examined the ability of CD8\(^{+}\) T cells primed by immunization with DC exposed to the IDD B8R\(_{20-27}\), to protect against lethal ECTV challenge. In a first experiment, we found that B8R\(_{20-27}\)-pulsed DCs induced low but measurable CD8\(^{+}\) T cell responses (unpublished data) and protection from intranasal challenge with ECTV that was significant (\(P = 0.0279\)), but incomplete (Fig. 6 a). This protection was confirmed in a second experiment controlled with groups of mice immunized with TK\(^{−/H11002}\) VACV and DCs pulsed with an irrelevant peptide (\(P = 0.0196\); Fig. 6 b). These data demonstrate that the IDD, B8R\(_{20-27}\), not only cross-reacts amongst poxvirus species but is also cross-protective.

DISCUSSION

The large coding capacity of poxvirus genomes presents a challenge for determinant mapping. Consequently, it is tempting to use various criteria to winnow the number of determinant candidates. The results demonstrated that the CD8\(^{+}\) T cell response to B8R\(_{20-27}\) is immunodominant in VACV infection and is partially cross-protective. This suggests that the B8R\(_{20-27}\) determinant may be a conserved epitope within the family of poxviruses.
genes to be considered. Virus late genes are often excluded in determinant screens (6, 7). VACV-determinant mapping projects also use conservation between orthopoxviruses as a determinant selection criteria (6–8). Our results show that both criteria are seriously flawed. We discovered an immunogenic determinant in A42R, considered to be a late gene product (32). In addition, we provide several examples in which the immunogenicity of determinants in poxviruses cannot be predicted from the conservation of their sequence and integrity of their source ORFs according to sequences in the available databases. Furthermore, conserved determinants may easily be missed because fragments of known genes are not always included in annotations of poxvirus genome, as was the case for the B8R20–27 determinant from B8R in the original MVA sequence. Finally, practical considerations aside, a complete understanding of cross-protection requires knowledge not only of the determinants two viruses have in common, but the ones that are unique to each infection.

The identification of the immunogenic determinants in poxviruses should greatly facilitate development of the mouse model for smallpox vaccination and also the utility of mouse poxvirus infections for understanding viral immunity. The latter point is underscored by our observation that the ID hierarchy varies with the route of infection, the first observation of its kind to our knowledge. It will be of great interest to determine the underlying mechanism. It could reflect route-dependent differences in the identity of antigen-presenting cells that activate CD8+ T cells, the nature of antigen presented (e.g., direct vs. cross-priming), or the repertoire of CD8+ T cells that interact with antigen-presenting cells in the locale where priming occurs. Understanding route-dependent effects on immunogenicity is critical to interpreting vaccine trials such as the recent paper comparing intramuscular immunization with MVA to standard scarification with Dryvax (33).

We found that the ID hierarchy amongst SDDs was greatly altered in mice immunized with MVA compared with WR. Furthermore, responses to two VACV determinants that were always detectable in mice infected by the i.p. route with WR were at background levels when MVA was used. Experiments with another highly attenuated VACV (iA17L) demonstrate that the results found with MVA cannot be attributed per se to decreased replication in vivo. Sequencing database searches found these two determinants and their genes intact and expected to be expressed in two separate isolates of MVA, one of which is derived from the same source as our MVA stock. Furthermore, DNA sequencing of our virus stock revealed no alterations in the determinants. It is more likely that the altered ID hierarchy is related to one or more of the many genomic deletions and other changes in MVA compared with WR (34). It is possible that MVA encodes a novel IDD that suppresses other responses via immunodomination (23). Alternatively, genes encoding the cryptic determinants may not be expressed at immunogenic levels by MVA in vivo. Irrespective of the cause, the finding that responses were not predictable on the basis of sequence information challenges assumptions about conservation of CD8+ T cell responses between related viruses and underscores the need for empirical data. It also raises the important issue of the degree of overlap between cellular immune responses to Dryvax and potential smallpox vaccine replacements.

Using the VACV/ECTV model, we identify the first VACV-CD8+ T cell determinant that may mediate cross-protection against a lethal systemic disease with a heterologous poxvirus. This extends prior studies with individual CD8+ T cell determinants using VACV challenge models in HLA-A2 transgenic mice (6, 8) and shows the potential of CD8+ T cells to mediate protection against poxvirus disease. Immunization with B8R20–27 synthetic peptide provided incomplete protection in our challenge model, but we note that the number of CD8+ T cells induced by peptide vaccination was at least 50-fold less than after VACV infection, and inducing higher CD8+ T cell responses could well provide better protection. Furthermore, although our data show a potential basis for cross-protection between orthopoxviruses, more work is needed to understand the roles of CD8+ T cells and other effector mechanisms in the context of current VACV-based vaccines.

**MATERIALS AND METHODS**

**Viruses and cell lines.** VACV strains WR, MVA, Vsc8 (30), and iA17L (29); ECTV strain Moscow; and CPXV strain Brighton were grown and titrated using standard methods. Dryvax smallpox vaccine was obtained from the Centers for Disease Control, Atlanta. Titrated stocks of MVA and titration of Dryvax were provided by L. Wyatt (National Institute of Infectious Diseases [NIAID], Bethesda, MD). 293A cells were maintained in Dulbecco’s Modified Eagle Medium with 10% FBS, and DC2.4 (35) and EL-4 were maintained in D10 or RPMI 1640 medium with 10% FBS (R10). All media was from Invitrogen. For use as stimulators in CD8+ T cell assays, 1–5 × 10^6 DC2.4 were infected with VACV at 5–10 PFU/cell in <200 µl of PBS at 37°C for 30–60 min with occasional shaking. After this initial incubation, 9 ml R10 was added, and the incubation continued until a total time after infection of at least 4 h. Infected cells were spun and washed, and the appropriate number was added to T cell assays.

**Synthetic peptides.** Peptides were synthesized as described previously (36) by A & A Labs, at the John Curtin School of Medical Research Biomolecular Resources Facility (Australian National University, Canberra, Australia) or purchased as crude material from Mimotopes or Pepscan Systems B.V. Peptides were resuspended at 4–20 µg/ml in 100% DMSO and diluted to required concentrations in PBS, PBS with 0.05% NP-40, or RPMI 1640. Peptides for use as radiolabeled probes were purified to >95% homogeneity by reversed phase HPLC, and composition was ascertained by amino acid analysis, sequencing, and/or mass spectrometry analysis. Radiolabeling was done using the chloramine T method (37).

**Enrichment of splenic DCs.** DCs were enriched from C57BL/6 mouse spleens essentially as described previously (38). In brief, spleen fragments were digested for 20 min at room temperature with collagenase-DNase and treated for 5 min with EDTA. Low-density cells (including DCs) were selected by centrifugation in a Hepes-buffered balanced salt solution, pH 7.2, with 3% FCS and Nycodenz at a density of 1.077 g/cm³ (Nycocell). The DC-enriched fraction was cultured overnight at 37°C with 5% CO₂ in DMEM (high glucose) with 10% FBS and 100 ng/ml LPS. The nonadherent population from this culture was collected. Enriched DCs were incubated with peptide at 1 µM for 2 h before washing and resuspension in PBS.
Mice, infections, and immunizations. Specific pathogen-free C57BL/6 mice were obtained from Taconic, Animal Resource Centre (Perth, Australia), and Animal Services Division, John Curtin School of Medical Research. Mice were housed, and experiments were done according to the relevant ethics requirements. In most experiments, mice were infected i.p. with $10^5$–$10^7$ PFU of VACV, depending on virus strain. For dermal scarification, 10 scratches were made at the base of the tail in a cross hatch pattern using a 21 gauge needle and a drop of VACV at $10^7$ PFU/ml applied for 1 min before the excess was removed with a tissue. For subcutaneous infections, $10^6$ PFU ECTV and $10^9$ PFU CPVX and VACV were injected in the shanks of mice. Except where stated, mice were euthanized 7 d after infection and spleens taken for analysis of CD8$^+$ T cell responses. For DC immunization, 2.5 x 10^5 peptide-coated, spleen-derived DCs suspended in PBS were injected intravenously. For ECTV challenge, DC-immunized or control mice were anesthetized and infected intranasally with 300 PFU of ECTV in 20 μl of PBS. Mice were monitored for signs of illness twice daily, and moribund animals euthanized.

It was noted that C57BL/6 mice available in Australia (from two sources) made very high VACV-specific responses (Fig. 2–5). Mice available in the USA had lower total VACV-specific responses in the spleen (20–25% responses) as contrasted to the responses from the Australian mice (Fig. 2B). It was noted that C57BL/6 mice available in Australia (from two sources) made very high VACV-specific responses (Fig. 2–5). Mice available in the USA had lower total VACV-specific responses in the spleen (20–25% responses) as contrasted to the responses from the Australian mice (Fig. 2B). The complete library comprised 258 unique clones each ORF clone was sequenced using ABI BigDye Terminators reagents (Aldevron), and inserted in the shanks of mice. Except where stated, mice were euthanized 7 d after infection and spleens taken for analysis of CD8$^+$ T cell responses. For DC immunization, 2.5 x 10^5 peptide-coated, spleen-derived DCs suspended in PBS were injected intravenously. For ECTV challenge, DC-immunized or control mice were anesthetized and infected intranasally with 300 PFU of ECTV in 20 μl of PBS. Mice were monitored for signs of illness twice daily, and moribund animals euthanized.

It was noted that C57BL/6 mice available in Australia (from two sources) made very high VACV-specific responses (Fig. 2–5). Mice available in the USA had lower total VACV-specific responses in the spleen (20–25% responses) as contrasted to the responses from the Australian mice (Fig. 2B). The complete library comprised 258 unique clones each ORF clone was sequenced using ABI BigDye Terminators reagents (Aldevron), and inserted in the shanks of mice. Except where stated, mice were euthanized 7 d after infection and spleens taken for analysis of CD8$^+$ T cell responses. For DC immunization, 2.5 x 10^5 peptide-coated, spleen-derived DCs suspended in PBS were injected intravenously. For ECTV challenge, DC-immunized or control mice were anesthetized and infected intranasally with 300 PFU of ECTV in 20 μl of PBS. Mice were monitored for signs of illness twice daily, and moribund animals euthanized.

Generation of VACV ORF library. Primary PCR products were cloned into the pGEM-T vector system (Promega) and transformed in E. coli (strain DH5α). The complete library comprised 258 unique clones each representing a single predicted VACV ORF. The 5′ end (~600 bp) of each ORF clone was sequenced using ABI BigDye Terminators reagents and an ABI PRISM 3100 genetic analyzer (Applied Biosystems). Clones with early terminations or frame shifts were removed and remade. Transformation of Escherichia coli strain DH5α was done by the electroporation method (low endotoxin) DNA for each clone was produced by Aldion.

Generation of 293 cells expressing mouse MHC genes. The complete coding sequences for H-2K$^{b}$ and D$^{b}$ were amplified by PCR from recombinant VACV encoding these products and cloned into pcDNA3.1D/V5-His-TOPO as described before. The following primers were used: K$^{b}$, 5′-CACCATGTTACGCTGTCG-3′ and 3′-TCAGCTGTTACGCTGTCG-3′; and D$^{b}$, 5′-CACCAATGCGGCGCAGTC-3′ and 3′-TCAGCTGTTTCACTTCGAG-3′. All clones were sequenced by the manufacturer’s instructions. Clones were screened by cleavage of miniprep DNA (Wizard SV 96; Promega) with BamHI (site underlined in the aforementioned primer sequence) and separation on 1% agarose gels. This initial library was edited, with 12 duplicated ORFs being removed and four ORFs (known to exist but missing) being added (A13L, A14.5L, A44L, and A48R); ORFs were PCR amplified directly from crude virus stocks and cloned as described before. The complete library comprised 258 unique clones each representing a single predicted VACV ORF. The 5′ end (~600 bp) of each ORF clone was sequenced using ABI BigDye Terminators reagents and an ABI PRISM 3100 genetic analyzer (Applied Biosystems). Clones with early terminations or frame shifts were removed and remade. Transformation of E. coli DH5α was done by the electroporation method (low endotoxin) DNA for each clone was produced by Aldion.

MHC binding assays. Quantitative assays to measure the binding of peptides to soluble class I molecules are based on the inhibition of binding of a radiolabeled standard peptide (37). In brief, 1–10 nM radiolabeled peptide was coincubated at room temperature with 1 μM to 1 nM of purified class I molecules (from EL-4) in the presence of 1 μM of human β2-microglobulin (Scrpps Laboratories) and a cocktail of protease inhibitors. The radiolabeled peptides were used, and their average IC50s were RGYVFQGL, 3.1 nM and SGPSTYPEI, 4.4 nM for K$^{b}$ and D$^{b}$, respectively (41). After a 2-d incubation, binding of the radiolabeled peptide to the corresponding MHC class I molecule was determined by capturing MHC–peptide complexes on Greiner Lumitrac 600 microplates (Greiner Bio-one) coated with the W6/32 antibody, and measuring bound cpm using the TopCount microscintillation counter (Packard Instrument Co.). In the case of competitive assays, the concentration of peptide yielding 50% inhibition of the binding of the radiolabeled probe peptide was calculated (IC50). Peptides were typically tested in three or more independent experiments. Under the conditions used, where [label] < [MHC] and IC50 ≥ [MHC], the measured IC50 values are reasonable approximations of the true Kd values (42).

Sequence comparison. ORF and determinant conservation between poxviruses was done with the aid of poxvirus orthologous clusters (43)
maintained at the University of Victoria, Victoria, BC Canada and accessed through the Poxvirus Bioinformatics Resource (www.poxvirus.org).

Statistical analysis. Statistical analysis was done with the aid of Prism software (Graphpad). For comparing the means of responses or ratios, Student’s t tests were used. For Kaplan-Meier survival analyses, p-values were generated using the log-rank test to compare survival curves. Differences were considered significant if p-values were <0.05.

We thank Dr. B. Moss for providing PCR products for the VACV ORF library and helpful discussions; Dr. L. Wyatt for titred stocks of MVA and Dryvax; C. Eigi and the National Institute of Allergy and Infectious Diseases (NIAID) flow cytometry section for single cell sorting; and D. Tokarzick and L. Morrison for technical assistance.

This work was funded by the NIAID-National Institutes of Health (NIH) intramural program and grants from the NHMRC (Australia) to D. Tscharke (Howard Florey Centenary Fellowship, no. 224273) and G. Karupiah (no. 153836), the Howard Hughes Medical Institute (to G. Karupiah), and NIAID-NIH to A. Sette and J. Sidney (R01 grant no. AI65268 and contract no. N01-AI-40023). The authors have no conflicting financial interests.

Submitted: 16 September 2004
Accepted: 22 November 2004

REFERENCES